武肺疫情輾轉覆轍,加上唔少人士直到依一刻依然唔信武肺存在,又或者唔怕武肺唔戴口罩、「我生病我的事」,導致感染人數經常出現技術性反彈。461Please respect copyright.PENANACOw9wmUd4l
461Please respect copyright.PENANAa7XU5SJeNg
武肺疫苗一直被媒體渲染為扭轉全球疫情的唯一辦法,但實際上一直黑過黑森林的黑馬一直在漆黑中默默奔跑,隨時會跑快過各種疫苗率先進入市場。461Please respect copyright.PENANA4pLgTzqvHO
461Please respect copyright.PENANAFfOiEcMsN0
依一隻黑馬,就係人造抗體。461Please respect copyright.PENANA5E7gnsZgJA
461Please respect copyright.PENANATvcwB8rRjp
疫苗的最終目的,就係想誘導人體自行製造抗體,達收拾武肺之效。461Please respect copyright.PENANAR8uHkdfG3A
461Please respect copyright.PENANAw4B6fKontO
有唔少生物科技公司認為,與其花費時間製造疫苗,倒不如以人造的方式製作疫苗的最終產物「抗體」,豈不是更加直接快捷?461Please respect copyright.PENANAKuivvQw28j
461Please respect copyright.PENANANx7672Yoj4
就喺今年六月初,禮來公司(Lilly)宣佈進行人造抗體LY-Cov555的Phase1臨床測試(Ref1),LY-Cov555係一隻針對武肺S protein位置的人造抗體,簡單啲嚟講,佢主要功用就係黏住武肺病毒與人體細胞的接觸面,令到病毒無辦法辨認細胞,失去入侵人體細胞的手段。461Please respect copyright.PENANANlHXW5S6AD
461Please respect copyright.PENANAOBXpXBKEYI
除禮來之外,雷傑納榮製藥(Regeneron)亦宣佈即將會進行Phase3臨床試驗,佢哋將會以人造方式製造一名武肺康復人士的抗體再加以一隻由老鼠而嚟的武肺抗體,用上二合一的方式進行測試(Ref2)。461Please respect copyright.PENANAjJJVYq47l2
461Please respect copyright.PENANAUTbLGthRc1
佢哋所製作的人造抗體有學術文章指出,將能夠辨認得到現今的所有武肺變種,包括時下大流行的D614G變種,聽起上嚟的確非常令人振奮。461Please respect copyright.PENANAUdeCrZj16D
461Please respect copyright.PENANAVlWr9lpfXb
而最值得注意的係,人造抗體的臨床治療所需時間一般會比疫苗的臨床治療為快。原因係就疫苗嚟講,通常要一定的時間過後身體免疫系統先會開始製造抗體,隨後先可以進行測試。461Please respect copyright.PENANAvvjJB7LcgG
461Please respect copyright.PENANANrmYx4kXKK
但人造抗體只要一注射入體內,有就有,無就無,相對上好快就可以進行所需的測試。461Please respect copyright.PENANAS5bd3TY7A6
461Please respect copyright.PENANA936fMohDsb
所以呢,人造抗體依一隻黑馬,絕對係有機會跑快過疫苗進入商業市場的。461Please respect copyright.PENANAQWrNbRgQ0g
461Please respect copyright.PENANAbKICeP1vac
不過當然,論長遠嚟講,疫苗絕對比人造抗體更能提供更長遠及實際的保護效果。461Please respect copyright.PENANAIuPY0hWa16
但就當今現時局勢嚟講,疫苗某程度上只係「遠水」,人造抗體先係「近水」,有效撲滅武肺「近火」。461Please respect copyright.PENANArfgR7SqFkj
461Please respect copyright.PENANAhjhXEPTCOi
461Please respect copyright.PENANAAvX3oz4jdn
某兩款康復病人對抗武肺抗體(綠色及橙色)的示意圖,白色為武肺與人體細胞接觸所需的S protein。裡頭的紅點及藍點為現今所知的武肺變種位置,無一個變種位置可以阻撓抗體與其結合。461Please respect copyright.PENANAcu9OXq6dT8
461Please respect copyright.PENANAwUtBb1u1Wm
Ref1: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody461Please respect copyright.PENANALjaoKyX3w9
Ref2: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention/461Please respect copyright.PENANA1Br4drsn5O